Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Provectus Pharmaceuticals has received allowance of a second US patent application protecting a novel photoactive analog of its lead photodynamic product PH-10, from the US Patent and Trademark Office.
Subscribe to our email newsletter
The pending patent covers systemic use of the drug, PH-12, for photodynamic treatment of cancer, skin diseases, and other tissue disorders using visible light activation.
Craig Dees, CEO of Provectus, said: “While we remain focused on clinical development of our lead therapeutic products, PV-10 for cancer and PH-10 for dermatology, this new patent will further solidify an important longer-term opportunity in our development pipeline. It is likely to be some time before we commence clinical testing of PH-12, but given the large potential value in markets worldwide, protection of this new technology enhances value for our shareholders now.”